Lisata TherapeuticsLSTA
Market Cap: $25.1M
About: Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
Employees: 25
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
13% more capital invested
Capital invested by funds: $2.31M [Q1] → $2.61M (+$300K) [Q2]
5% more funds holding
Funds holding: 21 [Q1] → 22 (+1) [Q2]
0.13% more ownership
Funds ownership: 8.92% [Q1] → 9.05% (+0.13%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 99 / 262 met price target | 397%upside $15 | Buy Reiterated | 18 Sept 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 99 / 262 met price target | 397%upside $15 | Buy Reiterated | 13 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 99 / 262 met price target | 397%upside $15 | Buy Reiterated | 19 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 99 / 262 met price target | 397%upside $15 | Buy Reiterated | 10 Jul 2024 |
Financial journalist opinion
Based on 4 articles about LSTA published over the past 30 days